Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Operations: 2015-2025

Historic Cash from Operations for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$67.8 million.

  • AC Immune's Cash from Operations fell 315.37% to -$67.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.1 million, marking a year-over-year decrease of 316.62%. This contributed to the annual value of $75.2 million for FY2024, which is 209.60% up from last year.
  • Latest data reveals that AC Immune reported Cash from Operations of -$67.8 million as of Q3 2025, which was down 246.47% from -$19.6 million recorded in Q2 2025.
  • AC Immune's Cash from Operations' 5-year high stood at $80.8 million during Q2 2024, with a 5-year trough of -$67.8 million in Q3 2025.
  • In the last 3 years, AC Immune's Cash from Operations had a median value of -$16.3 million in 2024 and averaged -$9.5 million.
  • Per our database at Business Quant, AC Immune's Cash from Operations skyrocketed by 611.76% in 2024 and then plummeted by 1,935.27% in 2025.
  • AC Immune's Cash from Operations (Quarterly) stood at -$19.3 million in 2021, then climbed by 6.55% to -$18.1 million in 2022, then dropped by 2.14% to -$18.5 million in 2023, then surged by 136.70% to $6.8 million in 2024, then tumbled by 315.37% to -$67.8 million in 2025.
  • Its Cash from Operations stands at -$67.8 million for Q3 2025, versus -$19.6 million for Q2 2025 and -$21.5 million for Q1 2025.